A 38-year-old man with a 10-year history of type 2 diabetes presents with recurrent hypoglycaemic episodes despite stable insulin dosing. His fasting blood glucose is 85 mg/dL, but he experiences tremors and sweating at glucose levels of 120 mg/dL. On investigation, his plasma glucagon levels are inappropriately low during hypoglycaemia (2 pg/mL; normal 50–100 pg/mL). A defect in the cAMP signalling pathway in pancreatic alpha cells is suspected. Which is the most appropriate next step in management?

Explanation

## Clinical Context This patient has **impaired glucagon counter-regulation** during hypoglycaemia — a hallmark of defective cAMP signalling in pancreatic alpha cells. Glucagon secretion is mediated by the **β~2~-adrenergic receptor → Gs protein → adenylyl cyclase → ↑cAMP → PKA activation → exocytosis of glucagon granules**. A defect anywhere in this cascade (receptor, Gs, adenylyl cyclase, or phosphodiesterase dysregulation) impairs the glucagon response. ## Why the Correct Answer is Right **Key Point:** In a patient with documented impaired glucagon counter-regulation and recurrent hypoglycaemia, the immediate clinical priority is **harm reduction and prevention**, not diagnostic tissue sampling or genetic testing. **High-Yield:** The management of hypoglycaemia-associated autonomic failure (HAAF) or defective counter-regulation follows a stepwise approach: 1. **Immediate:** Prevent further hypoglycaemic episodes (CGM, education, strict glycaemic targets) 2. **Short-term:** Provide emergency glucagon access (kit training) 3. **Longer-term:** Genetic/mechanistic diagnosis (if clinically indicated) Continuous glucose monitoring allows real-time detection of impending hypoglycaemia, enabling preemptive carbohydrate intake. Structured patient education on hypoglycaemia recognition and prevention is the **standard of care** and reduces recurrence by 40–50%. This is the next step because it is immediately actionable, evidence-based, and reduces morbidity. ## Why Each Distractor is Wrong | Option | Reason | | --- | --- | | Adenylyl cyclase/PDE biopsy | Invasive, not standard of care. Tissue biopsy does not guide acute management. Enzyme assays are research tools, not clinical practice. | | GLP-1 agonist monotherapy | GLP-1 receptors signal via cAMP but do NOT restore alpha-cell glucagon secretion in response to hypoglycaemia. GLP-1 agonists suppress glucagon inappropriately at low glucose. They are contraindicated as monotherapy in patients with defective counter-regulation. | | Genetic sequencing first | Genetic testing (GNAS, ADCY mutations) is appropriate for diagnosis but is **not the immediate next step**. It does not prevent the next hypoglycaemic episode. Sequencing is pursued after clinical stabilization and when a heritable syndrome is suspected. | ## Clinical Pearl **Warning:** Do not confuse **diagnostic workup** (biopsy, sequencing) with **clinical management**. In acute/recurrent hypoglycaemia, the priority is always **prevention and safety** first, diagnosis second. Genetic testing is a tertiary-level investigation reserved for familial or syndromic presentations. ## Mnemonic: cAMP Counter-Regulation Pathway **"GASP"** — **G**lucagon, **A**denylyl cyclase, **S**ignalling, **P**revention - **G:** Glucagon is the primary counter-regulatory hormone - **A:** Adenylyl cyclase (via Gs-coupled β~2~-AR) is the rate-limiting step - **S:** Signalling defects cause impaired secretion - **P:** Prevention (CGM, education) is the first-line management ## Management Algorithm ```mermaid flowchart TD A[Recurrent hypoglycaemia + low glucagon response]:::outcome --> B{Acute risk?}:::decision B -->|Yes| C[Implement CGM + patient education]:::action C --> D[Prescribe glucagon emergency kit]:::action D --> E[Clinical stabilization achieved]:::outcome E --> F{Diagnosis needed?}:::decision F -->|Yes, familial/syndromic| G[Genetic testing + tertiary referral]:::action F -->|No| H[Continue preventive management]:::action ```